12 research outputs found
Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study.
Experiencia clínica del tratamiento con onabotulinumtoxin A en pacientes con migraña refractaria
To analyse our experience in the treatment of refractory chronic migraine,
episodic frequent refractory migraine (>= 10 days/month), with onabotulinumtoxin
A (OnabotA). PATIENTS AND METHODS. Retrospective analysis of patients with
refractory migraine who underwent, at least two sessions of OnabotA pericranial
injections following the PREEMPT protocol between 2008 and 2012. The efficacy of
OnabotA was evaluated comparing the basal situation with 12-16 weeks after the
second session. We analysed the subjective improvement of the patients, number of
days with headache, preventive and abortive drugs consumption, and adverse
effects. RESULTS. Forty-one patients (37 women, 4 male) were identified. 65.8%
patients experienced subjective improvement after OnabotA treatment. 36.58%
responded (reduction of > 50% in headache days). Differences between days with
headache before the first session (24.5 +/- 7.3), and 12-16 weeks after the
second session (17.4 +/- 11.6), as well as the differences between the number of
abortive drugs taken before the first session (26.8 +/- 23.1) and 12-16 weeks
after the second session (16.7 +/- 19.3), were statistically significant (p <
0.001). Subgroups analysis showed that all differences were significant, except
for the reduction of the number of days with headache in patients with episodic
frequent refractory migraine. CONCLUSION. Our work shows that treatment with
OnabotA is safe and useful in patients with episodic and chronic refractory
migraine, including those patients with medication overuse headache
Refractory migraine in a headache clinic population
<p>Abstract</p> <p>Background</p> <p>Many migraineurs who seek care in headache clinics are refractory to treatment, despite advances in headache therapies. Epidemiology is poorly characterized, because diagnostic criteria for refractory migraine were not available until recently. We aimed to determine the frequency of refractory migraine in patients attended in the Headache Unit in a tertiary care center, according to recently proposed criteria.</p> <p>Methods</p> <p>The study population consisted of a consecutive sample of 370 patients (60.8% females) with a mean age of 43 years (range 14-86) evaluated for the first time in our headache unit over a one-year period (between October 2008 and October 2009). We recorded information on clinical features, previous treatments, Migraine Disability Assessment Score (MIDAS), and final diagnosis.</p> <p>Results</p> <p>Overall migraine and tension-type headache were found in 46.4% and 20.5% of patients, respectively. Refractory migraine was found in 5.1% of patients. In refractory migraineurs, the mean MIDAS score was 96, and 36.8% were medication-overusers.</p> <p>Conclusions</p> <p>Refractory migraine is a relatively common and very disabling condition between the patients attended in a headache unit. The proposed operational criteria may be useful in identifying those patients who require care in headache units, the selection of candidates for combinations of prophylactic drugs or invasive treatments such as neurostimulation, but also to facilitate clinical studies in this patient group.</p
Assessment of disease progression in dysferlinopathy: A 1-year cohort study
ObjectiveTo assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year.MethodsOne hundred ninety-three patients with dysferlinopathy were recruited to the Jain Foundation's International Clinical Outcome Study for Dysferlinopathy. Baseline, 6-month, and 1-year assessments included adapted North Star Ambulatory Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6-minute walk test (6MWT), Brooke scale, Jebsen test, manual muscle testing, and hand-held dynamometry. Patients also completed the ACTIVLIM questionnaire. Change in each measure over 6 months and 1 year was calculated and compared between disease severity (ambulant [mild, moderate, or severe based on a-NSAA score] or nonambulant [unable to complete a 10-meter walk]) and clinical diagnosis.ResultsThe functional a-NSAA test was the most sensitive to deterioration for ambulant patients overall. The a-NSAA score was the most sensitive test in the mild and moderate groups, while the 6MWT was most sensitive in the severe group. The 10-meter walk test was the only test showing significant change across all ambulant severity groups. In nonambulant patients, the MFM domain 3, wrist flexion strength, and pinch grip were most sensitive. Progression rates did not differ by clinical diagnosis. Power calculations determined that 46 moderately affected patients are required to determine clinical effectiveness for a hypothetical 1-year clinical trial based on the a-NSAA as a clinical endpoint.ConclusionCertain functional outcome measures can detect changes over 6 months and 1 year in dysferlinopathy and potentially be useful in monitoring progression in clinical trials.ClinicalTrials.gov identifier:NCT01676077
Refractory migraine in a headache clinic population
Many migraineurs who seek care in headache clinics are refractory to
treatment, despite advances in headache therapies. Epidemiology is poorly
characterized, because diagnostic criteria for refractory migraine were not
available until recently. We aimed to determine the frequency of refractory
migraine in patients attended in the Headache Unit in a tertiary care center,
according to recently proposed criteria. METHODS: The study population consisted
of a consecutive sample of 370 patients (60.8% females) with a mean age of 43
years (range 14-86) evaluated for the first time in our headache unit over a
one-year period (between October 2008 and October 2009). We recorded information
on clinical features, previous treatments, Migraine Disability Assessment Score
(MIDAS), and final diagnosis. RESULTS: Overall migraine and tension-type headache
were found in 46.4% and 20.5% of patients, respectively. Refractory migraine was
found in 5.1% of patients. In refractory migraineurs, the mean MIDAS score was
96, and 36.8% were medication-overusers. CONCLUSIONS: Refractory migraine is a
relatively common and very disabling condition between the patients attended in a
headache unit. The proposed operational criteria may be useful in identifying
those patients who require care in headache units, the selection of candidates
for combinations of prophylactic drugs or invasive treatments such as
neurostimulation, but also to facilitate clinical studies in this patient group
Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease
This study aims to determine clinically relevant phenotypic differences between the two most common phenotypic classifications in dysferlinopathy, limb girdle muscular dystrophy R2 (LGMDR2) and Miyoshi myopathy (MMD1). LGMDR2 and MMD1 are reported to involve different muscles, with LGMDR2 showing predominant limb girdle weakness and MMD1 showing predominant distal lower limb weakness. We used heatmaps, regression analysis and principle component analysis of functional and Magnetic Resonance Imaging data to perform a cross-sectional review of the pattern of muscle involvement in 168 patients from the Jain Foundation's international Clinical Outcomes Study for Dysferlinopathy. We demonstrated that there is no clinically relevant difference in proximal vs distal involvement between diagnosis. There is a continuum of distal involvement at any given degree of proximal involvement and patients do not fall into discrete distally or proximally affected groups. There appeared to be geographical preference for a particular diagnosis, with MMD1 being more common in Japan and LGMDR2 in Europe and the USA. We conclude that the dysferlinopathies do not form two distinct phenotypic groups and therefore should not be split into separate cohorts of LGMDR2 and MM for the purposes of clinical management, enrolment in clinical trials or access to subsequent treatments
Cardiac and pulmonary findings in dysferlinopathy: A 3-year, longitudinal study
INTRODUCTION/AIMS: There is debate about whether and to what extent either respiratory or cardiac dysfunction occurs in patients with dysferlinopathy. This study aimed to establish definitively whether dysfunction in either system is part of the dysferlinopathy phenotype. METHODS: As part of the Jain Foundation\u27s International Clinical Outcome Study (COS) for dysferlinopathy, objective measures of respiratory and cardiac function were collected twice, with a 3-y interval between tests, in 188 genetically confirmed patients aged 11-86 y (53% female). Measures included forced vital capacity (FVC), electrocardiogram (ECG), and echocardiogram (echo). RESULTS: Mean FVC was 90% predicted at baseline, decreasing to 88% at year 3. FVC was less than 80% predicted in 44 patients (24%) at baseline and 48 patients (30%) by year 3, including ambulant participants. ECGs showed P-wave abnormalities indicative of delayed trans-atrial conduction in 58% of patients at baseline, representing a risk for developing atrial flutter or fibrillation. The prevalence of impaired left ventricular function or hypertrophy was comparable to that in the general population. DISCUSSION: These results demonstrate clinically significant respiratory impairment and abnormal atrial conduction in some patients with dysferlinopathy. Therefore, we recommend that annual or biannual follow-up should include FVC measurement, enquiry about arrhythmia symptoms and peripheral pulse palpation to assess cardiac rhythm. However, periodic specialist cardiac review is probably not warranted unless prompted by symptoms or abnormal pulse findings
Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study
Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study
Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials.
International audienceBackground and objective Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathies had not been performed and previous imaging findings were not correlated with functional tests.Methods We present cross-sectional T1-weighted muscle MRI data from 182 patients with genetically confirmed dysferlinopathies. We have analysed the pattern of muscles involved in the disease using hierarchical analysis and presented it as heatmaps. Results of the MRI scans have been correlated with relevant functional tests for each region of the body analysed.Results In 181 of the 182 patients scanned, we observed muscle pathology on T1-weighted images, with the gastrocnemius medialis and the soleus being the most commonly affected muscles. A similar pattern of involvement was identified in most patients regardless of their clinical presentation. Increased muscle pathology on MRI correlated positively with disease duration and functional impairment.Conclusions The information generated by this study is of high diagnostic value and important for clinical trial development. We have been able to describe a pattern that can be considered as characteristic of dysferlinopathy. We have defined the natural history of the disease from a radiological point of view. These results enabled the identification of the most relevant regions of interest for quantitative MRI in longitudinal studies, such as clinical trials